Purpose

This study, with N = 85 participants minimum over 3 visits spread over 7 days, has been designed to assess the accuracy and precision of the Blood Pressure and pulse rate values as generated by Aktiia.product-G1-US for up to 7 days after initialization in a cohort of subjects representative of the US population.

Condition

Eligibility

Eligible Ages
Between 22 Years and 59 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Participants must be able to provide informed consent to participate. 2. Participants must be willing and able to comply with all of the study procedures and return for a second visit one week later. 3. Participants must be 22 to 59 years of age. 4. Participants or witnesses must be able to read or write in English.

Exclusion Criteria

  1. Participants with compromised circulation, injury, or physical malformation of the equipment test sites or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.) 6. Female participants who are known to be pregnant or who are trying to get pregnant confirmed by a visit 1 and, if applicable, visit 2 positive urine pregnancy test, unless the study participants are known to be not of child-bearing potential . 7. Participants with known history of clotting disorders or blood clots, or currently taking a prescription blood thinner. 8. Other known health conditions that will prevent safe participation in the study upon disclosure in Health Assessment Short Form or verbally. 9. Participants suffering from sporadic or sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including but not limited to tachycardia (heart rate at rest > 120bpm) and atrial fibrillation. 10. Participants suffering from sporadic or sustained reduction of peripheral perfusion that can lead to weak or unstable pressure pulses including but not limited to: Raynaud's disease, diabetes (Type I and Type II), renal dysfunctions (eGFR < 60mL / min / 1.73 m2), hyper- / hypothyroidism, pheochromocytoma, arteriovenous fistula, and valvular heart diseases. 11. A wrist circumference below 14 cm or above 23 cm. 12. An upper-arm circumference <22 cm or > 42cm. 13. Any subject that, in the opinion of the investigator, does not exhibit any phenotype relevant to the objectives of this study. 14. Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, or bias the results, by instance a subject presenting a lateral Blood Pressure difference at screening of more than 15 mmHg for the systolic and/or more than 10 mmHg for the diastolic.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Other
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
Aktiia.product-G1-US device under test
Blood pressure and pulse rate measurements will be taken at different timepoints with the device under test and references.
  • Device: Device under test evaluation against references
    Blood pressure and pulse rate measurements will be taken at different timepoints with the device under test and references. Main references: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate.

Recruiting Locations

Parameters Research Laboratory
Broomfield, Colorado 80021
Contact:
Arthur Cabrera Dr Med.
303-993-5217
art@parameterslab.com

More Details

Status
Recruiting
Sponsor
Aktiia SA

Study Contact

Anne Fedor Chief Clinical Research Officer
303-993-5217
anne@parameterslab.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.